Coverage with evidence development: Applications and issues

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 1, 2010, Pages 79-85

  Trueman, Paul ^a   Grainger, David L ^b   Downs, Kristen E ^c  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c Relevant Health Outcomes Inc   (United States)

Author keywords

Coverage with Evidence Development; Economics; Evidence based healthcare; Insurance coverage

Indexed keywords

CRITICAL CHALLENGES; DATA COLLECTION; DEGREE OF UNCERTAINTY; HEALTH TECHNOLOGY ASSESSMENTS; HEALTH-CARE INSURANCE; MEDICAL LITERATURES; NEW TECHNOLOGIES; REAL-WORLD;

INNOVATION; INSURANCE; TECHNOLOGICAL FORECASTING;

TECHNOLOGY TRANSFER;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; EVIDENCE BASED PRACTICE; HUMAN; REVIEW; APPARATUS, EQUIPMENT AND SUPPLIES; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH INSURANCE; INSURANCE; ORGANIZATION AND MANAGEMENT; RISK MANAGEMENT; SURGERY; TREATMENT OUTCOME;

PRESCRIPTION DRUG;

COST-BENEFIT ANALYSIS; EQUIPMENT AND SUPPLIES; EVIDENCE-BASED MEDICINE; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; PRESCRIPTION DRUGS; RISK SHARING, FINANCIAL; SURGICAL PROCEDURES, OPERATIVE; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 77949883892     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990882     Document Type: Review

References (19)

1. CCRE Therapeutics. Bosentan patient registry. 2005. http:// www.bosentanregistry.com.au/ (accessed February 16, 2009).
2. Centers for Medicare and Medicaid Services. National coverage determinations with data collection as a condition of coverage: Coverage with evidence development. 2006. http://www. cms.hhs.gov/mcd/ncpc-view-document.asp? id = 8 (accessed February 10, 2009).
3. Chalkidou K. Conditional reimbursment based on future research. ISPOR Connect. 2008;14:9-10.
4. Chapman S, Reeve E, Price D, Rajaratnam G, Neary R. Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care. Br J Cardiol. 2004;11:205-210.
5. Claxton K. Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals. Health Econ. 1999;8:269-274.
6. Claxton K. Pricing, innovation and NICE in the UK. Presented at the Second Biennial Conference of the American Society of Health Economists. Equity and efficiency in health and healthcare. 2008, June 22-25. Duke University.
7. Claxton K, SculpherMJ. Using value of information analysis to prioritise health research: Some lessons from recent UK experience (Conference Paper). Pharmacoeconomics. 2006;24:1055-1068.
8. Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. London: Department of Health; 2002.
9. Goeree R, Levin L. Building bridges between academic research and policy formulation: The PRUFE Framework-an Integral Part of Ontario's Evidence-Based HTPA Process. Pharmacoeconomics. 2006;24:1143-1156.
10. Hutton J, Trueman P, Henshall C. Coverage with evidence development: An examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23:425-435.
11. Medical Services Advisory Committee. Application 1006- Endoluminal grafting for abdominal aortic aneurysm. 2006. http://www.msac.gov.au/internet/ msac/publishing.nsf/Content/ app1006-1 (accessed February 20, 2009).
12. Medicare Australia. Physician's guide. A guide to prescribing treatment for primary pulmonary hypertension and pulmonary arterial hypertension within the Pharmaceutical Benefits Scheme Selection 100 restriction criteria. Sydney: Australian Government; 2008.
13. Multiple Sclerosis Resource Centre. Disease modifying drugs risk sharing scheme. 2002. http://www.msrc.co.uk/ index.cfm?fuseaction=show&pageid= 1893&CFID=8452005 &CFTOKEN=9967130 (accessed October 20, 2008).
14. Tracleer-A cornerstone of oral therapy. 2007. http://www. tracleer.com/default.asp?page=HCP-AboutTracleer&kw= bosentan&gclid= CPP88t7K-5gCFQ9Jagodah6ToQ (accessed February 5, 2009).
15. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393-1402.
16. Tunis S. Dealing with uncertainty in Medicare coverage decisions. Presented at the Health Technology Assessment International Annual Meeting. 2008. Montreal, Canada.
17. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'Coverage with Evidence Development'. Health Aff (Millwood). 2006;5:1218-1230.
18. Steinberg EP, Tunis S, Shapiro D. Insurance coverage for experimental technologies. Health Aff (Millwood). 1995;14:143-158.
19. Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia. Pharmacoeconomics. 2006;24:903-915.